Skip to main content

Table 3 Matrix table of annualised relapse rate ratios (standard errors) for an NMA of all RCTs (above the diagonal) and those obtained from the NMA of the RCTs and RWE combined (below the illustrated diagonal). Results presented at face value with no adjustments made for the inclusion of RWE

From: The inclusion of real world evidence in clinical development planning

  Placebo Nataluzimab Fingolimod 1.25 Fingolimod 0.5 Avonex Rebif 22 Rebif 44 Copaxone Betaferon
Placebo   0.314 (0.03) 0.462 (0.03) 0.423 (0.03) 0.832 (0.06) 0.727 (0.07) 0.679 (0.05) 0.659 (0.04) 0.670 (0.05)
Nataluzimab 0.407 (0.07)   1.488 (0.20) 1.361 (0.20) 2.677 (0.30) 2.336 (0.30) 2.183 (0.30) 2.120 (0.30) 2.157 (0.3)
Fingolimod 1.25 0.455 (0.05) 1.150 (0.23)   0.918 (0.08) 1.808 (0.17) 1.581 (0.19) 1.476 (0.15) 1.433(0.14) 1.458 (0.15)
Fingolimod 0.5 0.413 (0.05) 1.045 (0.22) 0.916 (0.12)   1.977 (0.19) 1.728 (0.21) 1.614 (0.17 1.567 (0.16) 1.594 (0.17)
Avonex 0.783 (0.07) 1.977 (0.36) 1.742 (0.24) 1.920 (0.27)   0.877 (0.09) 0.818 (0.06) 0.795 (0.07) 0.808 (0.07)
Rebif 22 0.766 (0.08) 1.933 (0.36) 1.706 (0.26) 1.880 (0.30) 0.982 (0.10)   0.939 (0.08) 0.913 (0.10) 0.929 (0.10)
Rebif 44 0.7482 (0.08) 1.887 (0.35) 1.666 (0.26) 1.837 (0.30) 0.959 (0.10) 0.983 (0.11)   0.974 (0.07) 0.991 (0.09
Copaxone 0.601 (0.05) 1.517 (0.28) 1.338 (0.19) 1.474 (0.21) 0.771 (0.07) 0.790 (0.09) 0.809 (0.09)   1.019 (0.07)
Betaferon 0.700 (0.07) 1.768 (0.32) 1.559 (0.22) 1.718 (0.25) 0.897 (0.07) 0.920 (0.09) 0.943 (0.1) 1.170 (0.11)